Literature DB >> 28652453

Predictive Factors for Prolonged Urination Disorder After Permanent 125I Brachytherapy for Localized Prostate Cancer.

Hidehisa Mori1, Tomoharu Fukumori2, Kei Daizumoto2, Megumi Tsuda2, Yoshihito Kusuhara2, Tomoya Fukawa2, Yasuyo Yamamoto2, Kunihisa Yamaguchi2, Masayuki Takahashi2, Akiko Kubo3, Takashi Kawanaka3, Shunsuke Furutani3, Hitoshi Ikushima3, Hiro-Omi Kanayama2.   

Abstract

BACKGROUND: We assessed the change in LUTS after prostate brachytherapy to reveal factors for prolonged urination disorder.
MATERIALS AND METHODS: Four hundred and four patients received prostate brachytherapy at our institution and were followed-up for at least 2 years. We evaluated the correlation of mean IPSS changes and clinical factors. Using multivariate analysis, we also evaluated clinical factors with potential to delay IPSS resolution.
RESULTS: In cases with prostate volume more than 30 cm3, radiation dose to 90% of prostate volume (D90) more than 160 Gy, and radiation dose to 30% of the urethral volume (UD30) more than 240 Gy, mean IPSS levels were significantly higher, even 30 months after treatment. On multivariate analysis, baseline IPSS more than 8 points and D90 more than 160 Gy were significant predictors for delayed IPSS resolution.
CONCLUSION: Our data suggest that higher baseline IPSS and higher D90 were predictors for prolonged urination disorder. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Brachytherapy; lower urinary tract symptoms; prostate cancer

Mesh:

Substances:

Year:  2017        PMID: 28652453      PMCID: PMC5566936          DOI: 10.21873/invivo.11127

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  17 in total

1.  Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry.

Authors:  Marion P R Van Gellekom; Marinus A Moerland; Marco Van Vulpen; Harm K Wijrdeman; Jan J Battermann
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-20       Impact factor: 7.038

2.  The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.

Authors:  Mischel Neill; Gabrielle Studer; Lisa Le; Michael McLean; Ivan Yeung; Greg Pond; Juanita M Crook
Journal:  Brachytherapy       Date:  2007 Jul-Sep       Impact factor: 2.362

3.  Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms before permanent prostate brachytherapy.

Authors:  Carys Thomas; Mira Keyes; Mitchell Liu; Veronika Moravan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-18       Impact factor: 7.038

4.  Long-Term Efficacy and Toxicity of Low-Dose-Rate ¹²⁵I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer.

Authors:  Jeffrey A Kittel; Chandana A Reddy; Kristin L Smith; Kevin L Stephans; Rahul D Tendulkar; James Ulchaker; Kenneth Angermeier; Steven Campbell; Andrew Stephenson; Eric A Klein; D Allan Wilkinson; Jay P Ciezki
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-05-08       Impact factor: 7.038

5.  Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation.

Authors:  Juanita Crook; Michael McLean; Charles Catton; Ivan Yeung; John Tsihlias; Melania Pintilie
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-02-01       Impact factor: 7.038

6.  Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.

Authors:  Mira Keyes; Stacy Miller; Veronika Moravan; Tom Pickles; Michael McKenzie; Howard Pai; Mitchell Liu; Winkle Kwan; Alexander Agranovich; Ingrid Spadinger; Vincent Lapointe; Ross Halperin; W James Morris
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-12-26       Impact factor: 7.038

7.  Chronic Prostate Inflammation is Associated with Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention.

Authors:  J Curtis Nickel; Claus G Roehrborn; Ramiro Castro-Santamaria; Stephen J Freedland; Daniel M Moreira
Journal:  J Urol       Date:  2016-07-01       Impact factor: 7.450

8.  Impact of pre-implant lower urinary tract symptoms on postoperative urinary morbidity after permanent prostate brachytherapy.

Authors:  Jun Teishima; Hideo Iwamoto; Katsutoshi Miyamoto; Koichi Shoji; Hiroshi Masumoto; Shogo Inoue; Kanao Kobayashi; Mitsuru Kajiwara; Akio Matsubara
Journal:  Int J Urol       Date:  2012-07-31       Impact factor: 3.369

9.  Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil.

Authors:  Nobumichi Tanaka; Kazumasa Torimoto; Isao Asakawa; Makito Miyake; Satoshi Anai; Akihide Hirayama; Masatoshi Hasegawa; Noboru Konishi; Kiyohide Fujimoto
Journal:  Radiat Oncol       Date:  2014-12-29       Impact factor: 3.481

10.  Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer.

Authors:  Toshio Ohashi; Atsunori Yorozu; Shiro Saito; Tetsuo Momma; Toru Nishiyama; Shoji Yamashita; Yutaka Shiraishi; Naoyuki Shigematsu
Journal:  Radiat Oncol       Date:  2014-01-09       Impact factor: 3.481

View more
  1 in total

1.  Patient assessment of lower urinary tract symptoms using the international prostate symptom score following low-dose-rate prostate brachytherapy.

Authors:  J C Farris; R T Hughes; C R Steber; T E Craven; B A Frizzell
Journal:  Brachytherapy       Date:  2021-08-02       Impact factor: 2.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.